EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A landscape analysis of Japanese tolerability assessments in oncology drug development

Hiroe Kitagaki, Kentaro Takeda, Hanami Nojiri, Hideki Maeda

Cancer Treatment and Research Communications · 2026 · 49 · 101417

DOI: 10.1016/j.ctarc.2026.101417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Hiroe Kitagaki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-city, Tokyo 204-8588, Japan; …. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Drug loss in oncology therapies in Japan highlights the need to reduce operational and regulatory uncertainty in drug development. In oncology, regulatory requirements for Japanese Phase 1 studies that primarily assess tolerability in Japanese participants remain unclear. This lack of clarity may discourage sponsors from pursuing drug development in Japan, contributing to drug loss. We (1) characterized current practices of Japanese tolerability assessments through a landscape analysis and (2) identified factors associated with single-dose Japanese tolerability assessments. METHODS: We analyzed Japanese tolerability assessments among new oncology drugs approved in Japan during fiscal years 2015-2024. Trial characteristics were summarized, including study type, tumor type, and number of dose levels evaluated. Multivariable Firth's logistic regression was used to identify factors associated with single-dose Japanese tolerability assessments among 71 drugs. Predicted probabilities were estimated for combinations of key factors. RESULTS: Single-dose assessments were associated with (1) determination of the recommended phase 2 dose (RP2D) before the Japanese tolerability assessment, although a wide confidence interval suggested instability in this estimate, and (2) regulatory approval supported by multi-regional clinical trials (MRCTs) including Japan. Predicted probabilities showed an increase from 0.2% in the absence of both factors to 61.8% when both were present, although these estimates should be interpreted as exploratory. CONCLUSION: Incorporating a single-dose Japanese tolerability cohort within an MRCT after RP2D determination may represent one potential development strategy. This study may help better understand current Japanese tolerability assessment practices and potential development pathways for integrating Japan into global development programs.

Schlagwörter

Stichwörter der Autor:innen

Drug lossJapanOncologyTolerability assessment

Autor:innen und Institutionen

  • Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-city, Tokyo 204-8588, Japan; Early Clinical Development Clinical Operations, Astellas Pharma Inc.,…
  • Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-city, Tokyo 204-8588, Japan.
  • Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-city, Tokyo 204-8588, Japan. Electronic address: maeda@my-pharm.ac.jp.

Zitieren

APA

Kitagaki, H., Takeda, K., Nojiri, H., & Maeda, H. (2026). A landscape analysis of Japanese tolerability assessments in oncology drug development. Cancer Treatment and Research Communications, 49, 101417. https://doi.org/10.1016/j.ctarc.2026.101417

Vancouver

Kitagaki H, Takeda K, Nojiri H, Maeda H. A landscape analysis of Japanese tolerability assessments in oncology drug development. Cancer Treatment and Research Communications. 2026;49:101417. doi:10.1016/j.ctarc.2026.101417

BibTeX
@article{Kitagaki2026,
  author = {Kitagaki, Hiroe and Takeda, Kentaro and Nojiri, Hanami and Maeda, Hideki},
  title = {A landscape analysis of Japanese tolerability assessments in oncology drug development},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {49},
  pages = {101417},
  doi = {10.1016/j.ctarc.2026.101417}
}
Kostenlos starten →